Galderma Has Strong Fiscal Start To 2026

Galderma Group AG closed out Q1 2026 with net sales of $1.5 billion.

The gains were predominantly driven by volume and complemented by positive price and mix effects, underscoring the continued execution of its unique, growth-driven integrated dermatology strategy, officials said.

Widespread net sales growth of were 25.5% year-on-year at constant currency, aligned with strong growth performance across geographies and product categories, including Dermatological Skincare at an increase of 17.0% and Therapeutic Dermatology at an increase of 71.3%.

“Galderma’s strong first quarter results reflect our commitment to advancing dermatology and delivering innovative solutions for consumers and patients worldwide,” said CEO Flemming Ørnskov. “This marks a strong start to another year of key launches, sustained execution and scientific momentum, as well as the continued strengthening of our financial profile – all reinforcing our category leadership. Our integrated dermatology strategy continues to drive growth and we are well-positioned to build on this success throughout 2026.”

Dermatological Skincare

Dermatological Skincare net sales for the first quarter were $441 million, with year-on-year growth of 17.0% at constant currency.

Both Dermatological Skincare flagship brands, Cetaphil and Alastin, maintained strong growth momentum, also benefitting from a lower comparable base for the period. Growth was positive in both geographies, with particularly strong performance of Cetaphil in fast-growing international markets and of Alastin in the US. Outperformance in the category continues to be driven by focused execution, innovation and portfolio synergies, officials said.

Commercial execution remained strong, officials said, with e-commerce continuing as the fastest growing channel, including outstanding growth from Cetaphil in China. Alastin also strengthened partnerships with leading aesthetics clinics in the U.S. through Alastin Signature Practices, a premium in-office experience designed to elevate regenerative, peri-procedural skincare.

Galderma continued to support its core portfolio with differentiated innovation. For Cetaphil, this included the introduction of AM/PM Antioxidant Serums, a breakthrough daily system clinically designed to defend skin by day and support accelerated repair by night for sensitive, stressed skin. For Alastin, it included the US launch of Alastin Regenerating Skin Nectar with TriHex+ technology, a new formulation with our proprietary Octapeptide‑45 which helps reinforce skin structure, restore skin barrier and support long-term skin longevity.

Outlook

Galderma is confirming its full-year guidance for 2026, with net sales growth of 17-20% at constant currency and a Core EBITDA margin of approximately 26% at constant currency.